Short-term withdrawal of simvastatin induces endothelial dysfunction in patients with coronary artery disease: a

Hong Chen1, Jing-Yi Ren, Yan Xing

  • 1Department of Cardiology, Peking University People's Hospital, Beijing, China. chenhong0418@yahoo.com.cn

Insights

Stopping simvastatin therapy in coronary artery disease (CAD) patients acutely worsens endothelial function, causing vascular injury beyond cholesterol rebound. This effect is linked to reduced nitric oxide (NO) production.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Endothelial Biology

Background:

  • Coronary artery disease (CAD) patients exhibit impaired endothelial function.
  • Simvastatin therapy improves endothelial function in CAD patients.
  • Effects of statin withdrawal on endothelial function in CAD are largely unknown.

Purpose of the Study:

  • Investigate simvastatin withdrawal effects on brachial artery endothelial function in CAD patients.
  • Elucidate the underlying mechanisms of these effects.

Main Methods:

  • 30 CAD patients received simvastatin (20 mg) for 4 weeks.
  • Flow-mediated dilation (FMD) assessed via ultrasound at baseline, 4 weeks, and 1 week post-withdrawal.
  • Mechanisms studied in human umbilical vein endothelial cells (HUVECs) measuring nitric oxide (NO) production and eNOS mRNA.

Main Results:

  • Simvastatin withdrawal caused cholesterol rebound but FMD decreased significantly, falling below baseline.
  • FMD reduction was independent of LDL cholesterol changes.
  • In HUVECs, NO production and eNOS mRNA expression decreased significantly after simvastatin withdrawal.

Conclusions:

  • Abrupt simvastatin withdrawal abrogates benefits and induces vascular injury in CAD patients.
  • Mechanisms involve suppressed endothelial nitric oxide (NO) production, potentially dose-dependent.
  • Endothelial function decline is independent of cholesterol levels.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...